JP2002520282A - 慢性リンパ性白血病の処置のための方法および組成物 - Google Patents

慢性リンパ性白血病の処置のための方法および組成物

Info

Publication number
JP2002520282A
JP2002520282A JP2000558815A JP2000558815A JP2002520282A JP 2002520282 A JP2002520282 A JP 2002520282A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2000558815 A JP2000558815 A JP 2000558815A JP 2002520282 A JP2002520282 A JP 2002520282A
Authority
JP
Japan
Prior art keywords
patient
group
hydrogen
indole
etodolac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000558815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002520282A5 (https=
Inventor
フランシス エイ． ナーデラ，
ルース エル． シッザー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002520282A publication Critical patent/JP2002520282A/ja
Publication of JP2002520282A5 publication Critical patent/JP2002520282A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000558815A 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物 Pending JP2002520282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9246698P 1998-07-09 1998-07-09
US60/092,466 1998-07-09
US9487898P 1998-07-29 1998-07-29
US60/094,878 1998-07-29
PCT/US1999/015501 WO2000002555A1 (en) 1998-07-09 1999-07-08 Methods and compositions for the treatment of chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2002520282A true JP2002520282A (ja) 2002-07-09
JP2002520282A5 JP2002520282A5 (https=) 2006-10-05

Family

ID=26785713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000558815A Pending JP2002520282A (ja) 1998-07-09 1999-07-08 慢性リンパ性白血病の処置のための方法および組成物

Country Status (12)

Country Link
US (3) US6573292B1 (https=)
EP (1) EP1104297B8 (https=)
JP (1) JP2002520282A (https=)
AT (1) ATE315392T1 (https=)
AU (1) AU767586B2 (https=)
CA (1) CA2336932A1 (https=)
DE (1) DE69929440T2 (https=)
DK (1) DK1104297T3 (https=)
ES (1) ES2255287T3 (https=)
NZ (1) NZ509376A (https=)
PT (1) PT1104297E (https=)
WO (1) WO2000002555A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7361680B2 (en) 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
AU2003295336A1 (en) 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
TW200524940A (en) * 2003-10-02 2005-08-01 Salmedix Inc Indole derivatives
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2294186B1 (en) * 2008-05-20 2019-10-09 Incuron, Inc. Inducing cell death by inhibiting adaptive heat shock response
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
US8076366B2 (en) * 2009-01-15 2011-12-13 Cephalon, Inc. Forms of bendamustine free base
AU2011292044A1 (en) 2010-08-18 2013-04-04 Del Mar Pharmaceuticals Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
EP3795145A3 (en) 2011-08-17 2021-06-09 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EP2804602B1 (en) 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013169600A1 (en) 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN106572992A (zh) 2014-04-06 2017-04-19 英丘伦有限责任公司 用curaxins进行组合治疗
CN109689045A (zh) 2016-05-04 2019-04-26 因美制药公司 大麻素的局部制剂在治疗大疱性表皮松解症和相关结缔组织病症中的用途
US12357604B2 (en) 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028148A2 (en) * 1995-03-13 1996-09-19 Loma Linda University Medical Center Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998004527A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL107185C (https=) 1957-12-19
US3843480A (en) 1963-08-28 1974-10-22 D Dreher Dry dry transfer
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3843681A (en) 1971-06-01 1974-10-22 American Home Prod 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives
US3939178A (en) 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
US3974179A (en) 1971-06-01 1976-08-10 American Home Products Corporation 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3839178A (en) * 1972-10-05 1974-10-01 Gen Electric Potentiometric oxygen sensor
US4310509A (en) 1979-07-31 1982-01-12 Minnesota Mining And Manufacturing Company Pressure-sensitive adhesive having a broad spectrum antimicrobial therein
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPS5777617A (en) 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
IL61721A (en) 1980-12-16 1984-03-30 Blank Izhak Nitroglycerin preparations
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
US4460562A (en) 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4542012A (en) 1982-07-02 1985-09-17 Minnesota Mining And Manufacturing Company Film-forming composition containing an antimicrobial agent and methods
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
IT1153909B (it) 1982-12-17 1987-01-21 Sogimi Srl Polimeri reattivi per la cura di affezioni cutanee
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4585877A (en) 1985-05-06 1986-04-29 American Home Products Corporation Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4748252A (en) 1986-08-15 1988-05-31 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids
US4686213A (en) * 1986-08-15 1987-08-11 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
DK0727994T3 (da) 1992-03-13 2000-08-07 Sepracor Inc Anvendelse af antipyretiske og analgetiske præparater indeholdende optisk rent R-etodolac
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5599946A (en) 1995-05-30 1997-02-04 Teva Pharmaceutical Industries Ltd. 3-(2-trialkylsilyloxy)ethyl-7-ethyl-1H-indoles and method for their preparation
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
WO1997048391A2 (en) 1996-06-21 1997-12-24 Advanced Research And Technology Institute Methods and compositions comprising r-ibuprofen
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
AU8322401A (en) 2000-08-09 2002-02-18 Univ California Indole compounds useful for the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028148A2 (en) * 1995-03-13 1996-09-19 Loma Linda University Medical Center Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
WO1997003667A1 (en) * 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998004527A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Pyranoindole and carbazole inhibitors of cox-2
WO1998019649A2 (en) * 1996-11-05 1998-05-14 The Children's Medical Center Corporation Methods and compositions for inhibition of angiogenesis

Also Published As

Publication number Publication date
DE69929440T2 (de) 2006-08-17
DK1104297T3 (da) 2006-05-29
EP1104297A1 (en) 2001-06-06
US20050261356A1 (en) 2005-11-24
AU767586B2 (en) 2003-11-20
NZ509376A (en) 2003-10-31
ATE315392T1 (de) 2006-02-15
CA2336932A1 (en) 2000-01-20
EP1104297B1 (en) 2006-01-11
AU5209899A (en) 2000-02-01
US6921772B2 (en) 2005-07-26
EP1104297A4 (en) 2003-01-02
PT1104297E (pt) 2006-05-31
EP1104297B8 (en) 2006-05-03
DE69929440D1 (de) 2006-04-06
ES2255287T3 (es) 2006-06-16
WO2000002555A1 (en) 2000-01-20
US20030232874A1 (en) 2003-12-18
US6573292B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
JP2002520282A (ja) 慢性リンパ性白血病の処置のための方法および組成物
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
CN108289960B (zh) Ep4受体拮抗剂用于治疗nash相关肝癌的用途
JPH10513463A (ja) うっ血性心不全の治療へのカルバゾール化合物の利用
JP2002523447A (ja) ５−ｈｔ６アンタゴニストの使用
CN103228655A (zh) 咔唑和咔啉衍生物，及其制备方法和治疗应用
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
JP2025087716A (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
JP2003529542A (ja) 癌の治療のためのエトドラクの使用
EP1123702A1 (en) Analgesics
JP2022500485A (ja) グラピプラント単位剤形
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
HUP9904243A2 (hu) Eljárás a Fas expressziójának gátlására
KR100377280B1 (ko) 디아릴알킬피페리딘을함유하는다중-약물내성종양치료효력증강용약제학적조성물
EP1671631A2 (en) Compositions for the treatment of chronic lymphocytic leukemia
JP2003238414A (ja) 医薬組成物
Wechter et al. Pillsbury Winthrop LLP
HUP0401696A2 (hu) Angiotenzin-II receptor antagonistát tartalmazó gyógyászati készítmény
CN121177494A (zh) Ipi549和bmn673联合在治疗白血病中的应用
MXPA04003136A (es) Formulaciones farmaceuticas solidas en solucion suspension y emulsion conteniendo paracetamol acido ascorbico y loratadina.
WO2007020509A1 (en) Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
JP2004002353A (ja) 医薬組成物
JP2000191533A (ja) 鎮痛剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100423